Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CHKA | P35790 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.46 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9396214 | 0.84 | CA2 (0.59) | CA2CA12CA1CA9CHKA | |
| SCHEMBL479371 | 0.81 | CA2 (0.46) | CA2CA12CA1CA9CHKA | |
| SCHEMBL3821587 | 0.79 | CA2 (0.54) | CA2CA12CA1CA9CHKA | |
| SCHEMBL603099 | 0.79 | — | — | |
| SCHEMBL5433 | 0.79 | — | — | |
| SCHEMBL9286350 | 0.77 | CA2 (0.52) | CA2CA12CA1CA9CHKA | |
| SCHEMBL4073463 | 0.77 | CA2 (0.70) | CA2CA12CA1CA9CHKA | |
| Hydrochloric Acid SCHEMBL2855578 | 0.77 | CA2 (0.52) | CA2CA12CA1CA9CHKA | |
| SCHEMBL15689312 | 0.77 | CA2 (0.52) | CA2CA12CA1CA9CHKA | |
| Potassium SCHEMBL30601762 | 0.77 | CA2 (0.52) | CA2CA12CA1CA9CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023109883-A1 | AROMATIC HETEROCYCLE-SUBSTITUTED COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2023-06-22 | — | — | WO | disclosed |
| CN-109553641-B | Novel pincer-like metal complex and application thereof | 中国科学院上海有机化学研究所 | 2023-05-12 | — | — | CN | disclosed |
| US-11040956-B2 | Synthesis of omecamtiv mecarbil | AMGEN INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200308143-A1 | SYNTHESIS OF OMECAMTIV MECARBIL | AMGEN INC. | 2020-10-01 | — | — | US | disclosed |
| EP-2799435-B1 | POLY (ADP-RIBOSE) POLYMERASE INHIBITOR | CHENGDU DIAO PHARMACEUTICAL GROUP CO LTD (CN) | 2018-03-28 | — | — | EP | disclosed |
| US-9187430-B2 | Poly (ADP-ribose) polymerase inhibitor | CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD. (CN) | 2015-11-17 | — | — | US | disclosed |
| US-20150051211-A1 | POLY (ADP-RIBOSE) POLYMERASE INHIBITOR | CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD. (CN) | 2015-02-19 | — | — | US | disclosed |
| EP-2799435-A1 | POLY (ADP-RIBOSE) POLYMERASE INHIBITOR | Chengdu Di'ao Pharmaceutical Group Co. Ltd. (CN) | 2014-11-05 | — | — | EP | disclosed |
| EP-1358157-A1 | CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002051806-A1 | CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308143-A1 | SYNTHESIS OF OMECAMTIV MECARBIL | SI, DPYD, MTHFD2 | CA2 1878/4885CA12 416/4885CA1 410/4885 |
| US-11040956-B2 | Synthesis of omecamtiv mecarbil | SI, DPYD, MTHFD2 | CA2 1878/4885CA12 416/4885CA1 410/4885 |
| US-20150051211-A1 | POLY (ADP-RIBOSE) POLYMERASE INHIBITOR | PARP1, PARP2, PARP11 | CA2 3658/4885CA12 3892/4885CA1 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.